Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edupression.com add-on to Esketamine for TRD
NCT04843462Unknown
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Randomised, open-label trial in major depressive disorder (MDD). Primary endpoints: Therapy response (observer-rated) at 12 weeks and Percentage of received esketamine treatments in relation to scheduled ones at 12 weeks. Status: unknown.
02
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04843462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843462.